ERG and OCT abnormalities in retinoblastoma after melphalan intravitreous injection

Albuquerque, Marina L de; Moreto, Renata; Bergamo, Maristella; Corrêa, Zélia M.; Jorge, Rodrigo

doi:10.5935/0004-2749.2021-0037

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 In children, RPE and electroretinography abnormalities were reported to be associated with the use of IVM. 8,[18][19][20] The retinal toxicity of IVM is thought to be dose-dependent and related to vascular changes such as occlusion or neovascularization or direct toxic effect. 20 We observed chorioretinal atrophy in the peripheral retina in five eyes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intravitreal Melphalan Injection as a Second-Line Local Therapy in Vitreoretinal Lymphoma

Guneri Beser,

Demirci

2024

Retina

View full text Add to dashboard Cite

Purpose: To evaluate the effectiveness and safety of intravitreal Melphalan(IVM) injection therapy in vitreoretinal lymphoma(VRL). Methods: Eight eyes of 5 biopsy-proven VRL patients who were treated with IVM injection as a second-line therapy after intravitreal Methotrexate(IVMTX) and Rituximab(IVR) injections were retrospectively evaluated between January 2011 and March 2023. Results: The medical records of five VRL patients (mean age of 62 years at the diagnosis) including four(80%) females and one(20%) male were retrospectively analyzed. Three patients(60%) either had a history of central nervous lymphoma or developed it during the follow-up. Patients were previously treated with a mean of 5 cycles of monthly IVMTX and IVR injections. All eyes showed complete response by the disappearance of vitreal and/or subretinal neoplastic cells within six weeks after IVM injections(range, 1-4 injections/eye). Of 12 IVM injections, three(25%) injections were associated with macular edema diagnosed on optical coherence tomography at one-month follow-up and resolved spontaneously within 5 months. The IVM administration induced new retinal pigment epithelium changes in 3 eyes(37%). Conclusion: IVM injection may be effective in the management of VRL as second-line local therapy. Randomized clinical trials with larger numbers of patients are needed to establish the efficacy, treatment protocol, and safety of IVM injection.

show abstract

Section: Discussionmentioning

confidence: 99%

“…8,[18][19][20] The retinal toxicity of IVM is thought to be dose-dependent and related to vascular changes such as occlusion or neovascularization or direct toxic effect. 20 We observed chorioretinal atrophy in the peripheral retina in five eyes. All eyes had some RPE changes in the peripheral fundus.…”

Section: Discussionmentioning

confidence: 99%